WO2012099422A2 - Composition et aliment naturel fonctionnel comprenant des extraits de lysimachiae foenum-graeci herba utilisés dans le traitement du cancer du cerveau - Google Patents

Composition et aliment naturel fonctionnel comprenant des extraits de lysimachiae foenum-graeci herba utilisés dans le traitement du cancer du cerveau Download PDF

Info

Publication number
WO2012099422A2
WO2012099422A2 PCT/KR2012/000504 KR2012000504W WO2012099422A2 WO 2012099422 A2 WO2012099422 A2 WO 2012099422A2 KR 2012000504 W KR2012000504 W KR 2012000504W WO 2012099422 A2 WO2012099422 A2 WO 2012099422A2
Authority
WO
WIPO (PCT)
Prior art keywords
brain cancer
composition
extract
present
brain
Prior art date
Application number
PCT/KR2012/000504
Other languages
English (en)
Korean (ko)
Other versions
WO2012099422A3 (fr
Inventor
황성연
정경채
Original Assignee
주식회사 한국전통의학연구소
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 한국전통의학연구소 filed Critical 주식회사 한국전통의학연구소
Publication of WO2012099422A2 publication Critical patent/WO2012099422A2/fr
Publication of WO2012099422A3 publication Critical patent/WO2012099422A3/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a novel use of Youngneung hyang extract. Specifically, the present invention relates to a therapeutic composition and functional food containing Yeongneung extract as an active ingredient exhibiting excellent preventive or therapeutic efficacy against brain cancer.
  • Brain cancer refers to abnormally increased proliferation of any type of neuron, also referred to as primary brain cancer, or any other cancer that metastasizes to the central nervous system (CNS), also referred to as brain metastasis.
  • CNS central nervous system
  • Primary brain cancer can only occur in those cases where the nerve cells lose their protective ability to undergo apoptosis.
  • Examples of primary brain cancers include, but are not limited to, neuroma, astrocytoma, neuroblastoma, glioma, meningioma, oligodendrocyte, stromal blastoma, spinal cord tumor and neuromyoma.
  • Gliomas comprise about 60% of all primary CNS tumors and typically occur in the cerebral hemispheres of the brain, but can be found in other areas such as the visual nerve, brain stem or cerebellum. Gliomas can be classified into groups according to the type of glial cell from which they originated (Kornblith et al, (1986), Cancer: Principles and Practice of Oncology, 2nd Ed., DeVita, V., Hellman, S., Rosenberg , S, eds., JB Lippincott Company, Philadelphia, Chapter 41: Neoplasms of the Central Nervous System). The most common type of glioma is astrocytoma. These tumors develop from star-shaped glial cells called astroglia.
  • Astrocytes are assigned a rating according to their malignancy.
  • Low-grade astrocytomas also known as grade I and II astrocytomas
  • Mid-grade astrocytoma also known as grade III astrocytoma
  • Grade III astrocytoma is treated with radiation and some chemotherapy following surgery.
  • High-grade astrocytoma also known as grade IV astrocytoma
  • Grade IV astrocytomas are usually treated with a combination of radiation and chemotherapy following surgery.
  • Glioblastoma multiforme is a grade IV astrocytoma, which is the most malignant and lethal primary brain tumor (Id).
  • Id primary brain tumor
  • the benefit of treatment is minimal, and treatment can significantly reduce the quality of the patient's short-lived life.
  • CNS tumors represent the most common group of solid tumors in young patients, there is a clear need in the art for primary brain cancer prevention and treatment methods that overcome the disadvantages of the above-mentioned conventional approaches.
  • Brain tumors are a secondary-induced cause of cancer-related death in infants, with approximately 25% of all such deaths, with current therapies in which most of these infants die within the first year of diagnosis.
  • Brain metastasis results from primary tumors elsewhere in the body, including, but not limited to, lung cancer (both small and non-small cell), breast cancer, colorectal cancer, prostate cancer, melanoma and pancreatic cancer. Particularly in patients with metastatic breast cancer, the incidence of brain metastasis is diagnosed at a rate of 10-20% (Tyson, R.M. et al, Therapy 3 (1), 97-112 (2006)).
  • Breast cancer is the second leading cause of cancer-related death in women, and nearly all deaths from breast cancer are due to metastatic disease with brain metastases found in 30% of patients at autopsy.
  • Standard modes of treatment include surgical resection, chemotherapy and radiation therapy, in particular whole-brain radiation therapy (WBRT) and stereotactic radiosurgery or combinations thereof.
  • Surgery for brain metastases can improve survival, especially in patients with a single lesion. Surgery, however, may not be possible in terms of multiple lesions, lesions that are difficult to surgically approach, or inability to withstand surgery. In breast cancer, 50% of patients with brain cancer metastases have multiple metastases, making them less suitable as surgical candidates.
  • WBRT can improve intermediate survival over untreated and as an adjuvant for surgery, it reduces the rate of relapse and dying nerve death, but does not change survival or level of action.
  • SRS provides a method for treating brain metastases that cannot be surgically resected by location or patient symptoms.
  • SRS provides an improvement in quality of life but does not provide survival benefits, except for patients with a single metastasis.
  • the use of chemotherapy in the treatment of brain metastases is hampered by the impossibility of high molecular weight compounds, limiting most chemotherapeutic agents across the blood brain barrier. This is reflected in the fact that chemosensitive tumors, such as most metastatic breast carcinomas, often exhibit a complete systemic response to chemotherapy simultaneously with tumor progression in the brain.
  • this initial resistance to the use of chemotherapy in the treatment of brain metastases has recently changed based on observations in animal models and human brain tumor autopsies, and metastatic lesions cause blood brain barrier insufficiency, whereby chemotherapy Drugs can always enter the tumor.
  • Radiation therapy combined with chemotherapy has evolved from a first-line approach in the treatment of brain metastases.
  • Brain cancer is a generic term for primary brain cancer that develops in the brain tissue and the envelope that surrounds the brain, and secondary brain cancer that has metastasized from cancer that occurs in the skull or other parts of the body.
  • Such brain cancers are often distinguished from cancers occurring in other organs.
  • lung, stomach, and breast cancers occur in one or two types of organs, and their properties are the same and similar.
  • the brain develops a wide variety of cancers. For example, glioblastoma multiforme, malignant gliomas, lymphomas, germ cell tumors, metastatic tumors, and the like.
  • glioma especially glioblastoma multiforme (GBM)
  • GBM glioblastoma multiforme
  • Yeongneung Lysimachiae foenum-Graeci herba is a biennial plant of the Primaceae family.
  • Huncho and Hyecho are dried spring flowers and plants of Yeongneunghyang.
  • the stem is about 70cm high, the leaves are alternate, and the leaf is double, and the flower stem comes out of the leaf axle in summer, and the small butterfly-shaped flower blooms.
  • the flower is used for headaches due to colds caused by abundant yarns, and it is used to treat bloating symptoms of thorax with fragrance. Originated in Europe, it is also distributed in Korea and is known to have analgesic, anti-inflammatory and whitening effects in oriental medicine.
  • the present inventors completed the present invention by confirming that the Yeongneung-hyang extract can effectively kill brain cancer cells during the study of herbal medicine for Yeongneung.
  • the present invention is ⁇ ⁇ , Lysimachiae foenum-Graeci herba) provides a composition for the prevention and treatment of brain cancer comprising an active ingredient extracted with an organic solvent.
  • the organic solvent is preferably ethanol.
  • the present invention Yeongneung Hyang (including food additives acceptable food supplements) ⁇ ⁇ , Lysimachia foenum-graecum Hance) Provides a functional food for preventing brain cancer, which contains an organic solvent extract as an active ingredient.
  • the present invention is Yeongneung ⁇ ⁇ , Lysimachiae foenum-Graeci herba) Provides a composition for preventing and treating brain cancer containing ethanol extract as an active ingredient.
  • the composition of the present invention includes Youngneung extract as an active ingredient, and may further include a pharmaceutically acceptable carrier or diluent.
  • the ethanol extract is preferably extracted for 24 hours at 50 °C, wherein the ethanol extract is more preferably dried and concentrated at 45 °C reduced pressure conditions, the ethanol is Most preferred is 95%.
  • the composition for preventing and treating brain cancer of the present invention, preferably comprises a pharmaceutically acceptable carrier or diluent.
  • the "pharmaceutically acceptable carrier” is a pharmaceutically acceptable substance such as a liquid or solid filler, diluent, excipient or solvent which serves to transport the active ingredient from one organ or part of the body to another organ or part of the body. , Composition or vehicle.
  • composition for treating brain cancer of the present invention may be prepared as a medicament by adding one or more pharmaceutically acceptable carriers together with the active ingredient.
  • the carrier may include, but is not limited to, saline, buffered saline, water, glycerol and ethanol, and any suitable agent known in the art (Remingtons's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA) may be used. .
  • the formulation for pharmacologically extracting Yeongneung extract of the present invention can be administered orally during clinical administration and can be used in the form of general pharmaceutical formulations, and when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrant And diluents such as surfactants or excipients.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc.
  • liquid preparations for oral use include suspensions, solvents, emulsions, and syrups.
  • various excipients may be included, such as wetting sweeteners, fragrances, preservatives and the like.
  • composition of the present invention may be administered in various parenteral formulations during actual clinical administration, and solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included.
  • preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • calcium or vitamin D 3 may be added to enhance the efficacy of the treatment.
  • Such compositions may be presented in unit-dose (single) or multi-dose (several) containers, such as sealed ampoules and vials, and immediately before use, sterile liquid carriers such as water for injection Can be stored under freeze-drying conditions requiring only the addition of. Immediate injection solutions and suspensions can be prepared from sterile powders, granules and tablets.
  • the formulations of the present invention can be applied differently depending on the age, sex, condition of the subject, the absorption of the active ingredient in the body, the inactivation rate and excretion rate, the drug used in combination.
  • the invention also includes formulations of dosage units.
  • the formulations are present in individual dosage forms, such as tablets, coated tablets, capsules, pills, suppositories, and ampoules, wherein the amount of active compound in the drug corresponds to the fraction or multiple of the individual dosage.
  • Dosage units may contain, for example, one, two, three or four times the individual dosage, or 1/2, 1/3 or 1/4 times.
  • the individual dosages preferably contain an amount in which the active compound is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dosage.
  • extract refers to an active ingredient isolated from natural products.
  • the extract may be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes an extract, a dry powder thereof, or any form formulated using the same.
  • Youngneung ethanol extract killed 99.9% of U-87 MG brain cancer cells at 100 ⁇ g / ml, and EC 50 (half maximal effective concentration) was 17.75 ⁇ g / ml.
  • the above results demonstrate that Youngneung extract of the present invention has excellent killing activity of U-87 MG cells and further has brain cancer treatment and prophylactic activity.
  • prevention means any action that inhibits or delays the onset of brain cancer by administration of the composition.
  • treatment means any action that improves or advantageously alters the symptoms of brain cancer by administration of the composition.
  • Youngneung extract in the present invention can be extracted by using water, an organic solvent, or a mixed solvent thereof. Preferably it is extracted using an organic solvent, in particular ethanol.
  • the extracted solution can be used directly or can be concentrated and / or dried.
  • methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof may be used and extracted by room temperature or warming under conditions where the active ingredient of the herbal medicine is not destroyed or minimized.
  • the degree of extraction and loss of the active ingredient of the drug may vary, so select an appropriate organic solvent.
  • the extraction method is not particularly limited, and examples thereof include cold needle extraction, ultrasonic extraction, reflux cooling extraction, and the like.
  • Filtration is a process of removing the suspended solid particles from the extract, it may be used to filter the particles using cotton, nylon or the like, or may be used, such as ultrafiltration, cryofiltration, centrifugal separation, but is not limited thereto.
  • Concentration of the extract may be used, such as concentrated under reduced pressure, reverse osmosis concentration.
  • the drying step after concentration includes freeze drying, vacuum drying, hot air drying, spray drying, reduced pressure drying, foam drying, high frequency drying, infrared drying, and the like. If desired, a process of grinding the final dried extract may be added.
  • the extract can perform an additional fractionation process.
  • the extract is suspended in distilled water to obtain a nonpolar solvent soluble layer by extraction and separation with a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • the term "pharmaceutically acceptable salts” means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases.
  • suitable acid include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, Formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like.
  • Salts derived from suitable bases may include alkali metals such as sodium, alkaline earth metals such as magnesium, ammonium and the like.
  • the pharmaceutical composition for preventing and treating brain cancer diseases of the present invention comprises 0.1 to 50% by weight of the extract or compound based on the total weight of the composition.
  • the composition does not increase the efficacy, but may include additional ingredients that are commonly used in the pharmaceutical composition to improve the smell, taste, time and the like.
  • the composition adds inorganic and organic additives such as vitamins B1, B2, B6, C, E, niacin, carnitine, betaine, folate pantothenic acid, biotin, zinc, iron, calcium, chromium, magnesium, and mixtures thereof. It can be included as.
  • the composition may include a substance having a therapeutic activity against brain cancer used alone or used in the past.
  • the term "patient” refers to humans and horses, sheep, pigs, goats, camels, who have a disease caused by brain cancer and its direct and indirect causes, and whose symptoms can be improved by administering the composition of the present invention. Means antelope, dog and other animals.
  • a composition comprising the extract of Youngneung, the above-described brain cancer can be effectively prevented and treated.
  • the composition of the present invention can be administered in parallel with existing brain cancer therapeutics.
  • the term "administration” means introducing a predetermined substance into a patient by any suitable method, and the route of administration of the composition of the present invention is oral or parenteral via any general route as long as the target tissue can be reached. May be administered.
  • the composition may be administered by any device in which the active agent may migrate to the target cell.
  • composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to a patient's sexually transmitted disease, age, severity, and drug activity.
  • the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. It may be single or multiple doses.
  • the method of administering the composition comprising the extract or compound prepared according to the preparation method of the present invention is preferably oral administration or intravenous administration.
  • the effective dose is oral administration, it is usually 1 to 1 time per adult. 500 mg / kg is preferred, and in the case of intravenous administration, 1 to 100 mg / kg is preferred, and may be administered 2-3 times a day.
  • Dosage levels for a particular patient may vary depending on sex, age, health condition, diet, time of administration, method of administration, drug mixture, the condition of the patient, and the extent of the onset of neurological disease.
  • the present invention also provides a functional food for preventing brain cancer containing Yeongreung Hyang (Lysimachiae foenum-Graeci herba) ethanol extract as an active ingredient comprising a food supplement acceptable food supplement.
  • Yeongreung Hyang Lisimachiae foenum-Graeci herba
  • ethanol extract as an active ingredient comprising a food supplement acceptable food supplement.
  • Functional food of the present invention preferably contains 0.1 to 5% by weight, more preferably 1% by weight of the ethanol extract relative to the total weight.
  • the present invention As a result of injecting the Yeongneung extract of the present invention into U-87 MG brain cancer cells, it was confirmed that U-87 MG brain cancer cells are killed (see FIG. 1 ). Therefore, it can be newly seen that the Yeongneung extract is effective in treating brain cancer.
  • the present invention was completed by preparing a functional food for brain cancer prevention containing Yeongneung-hyang extract as an active ingredient (see Preparation Example 2).
  • the Youngneung extract of the present invention inhibits the growth of brain cancer cells and induces apoptosis. Therefore, the composition for treating brain cancer according to the present invention will be very effective in the treatment of brain cancer patients.
  • FIG. 1 is a result of Alamar Blue analysis to determine the effect of the introduction of Yeongreung to the growth of brain cancer cells in human brain cancer U-87 MG cells.
  • the horizontal axis of the figure shows the concentration of the extract, the vertical axis shows the survival rate of brain cancer cells.
  • FIG. 2 is a result of Alamar Blue analysis to determine the effect of turmeric extract on the growth of brain cancer cells in human brain cancer U-87 MG cells.
  • the horizontal axis of the figure shows the concentration of the extract, the vertical axis shows the survival rate of brain cancer cells.
  • the obtained Yeongneung incense was stored in a dark place at room temperature and dried for 5 days.
  • the dried Yeongneung was crushed to a predetermined size.
  • the milled Yeongneung was immersed in 95% ethanol and extracted at 50 °C for 24 hours. It was dried and concentrated at 45 ° C. under reduced pressure.
  • the Youngneung extract of the obtained solid was stored at -20 ° C.
  • Alamar Blue analysis was performed on U-87 MG, a human brain cancer cell line, to investigate the effect of the Youngneung extract of solids obtained in Example 1 on the growth of brain cancer cells.
  • Alamar analysis is a modified form of the MTT assay, in which a compound that is decomposed by a specific enzyme is treated in living cells, and the relative number of living cells is determined after treatment with the drug by measuring the fluorescence intensity of the product as the compound is decomposed. I am an experimental method.
  • U-87 MG cells a brain cancer cell line used in the present invention, were distributed from the Korean Cell Line Bank (KCLB) and used for experiments.
  • MEM Minimum Essential Medium
  • FBS fetal bovine serum, fetal bovine serum
  • HEPES 4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid
  • the Youngneung extract extracted in Example 1 confirmed the cell growth inhibitory effect on U-87 MG brain cells. Specifically, 8.0 x 10 per each well in a 96 well plate 3 The Yeongneung infusing U-87 MG cells in dogs and dissolving them in dimethyl sulfoxide (DMSO) When the ethanol extract was treated at concentrations of 0 to 100 ⁇ g / ml (specifically, concentrations of 0, 3.125, 6.25, 12.5, 25, 50 and 100 ⁇ g / ml, respectively) for 48 hours, the degree of inhibition of cell growth was confirmed. (Table 1).
  • Turmeric is a substance that shows anticancer activity against various kinds of cancers such as lung cancer, uterine cancer and breast cancer.
  • the present inventors confirmed the effectiveness of the Youngneung extract of the present invention by confirming the extent of the turmeric on the growth of brain cancer cells.
  • the turmeric extract was confirmed the growth inhibition of the U-87 MG cells in the same manner as in Example 2, and the results are shown in Table 2 and FIG.
  • turmeric hardly reduced the growth of brain cancer cells even when the treatment concentration was high.
  • turmeric which is widely known as an anticancer substance, has almost no brain cancer treatment efficacy, whereas the Youngneung extract of the present invention has excellent U-87 MG cell killing activity, and further shows that it has brain cancer treatment and prophylactic activity.
  • EC50 refers to a concentration exhibiting an effect of 50% when the maximum effect that the Youngneung extract according to the present invention can exhibit 100%, it is referred to as a 50% effective concentration or 50% efficacy concentration. EC50 calculation resulted in a value of 17.75 ⁇ g / ml.
  • Youngneung used in the present invention was widely used as a medicinal herb, but it was determined that there is no problem in stability, but the oral administration and intraperitoneal toxicity experiments were performed to confirm this.
  • Acute toxicity test was performed using 6-week-old SPF SD rats. Two animals per group were suspended orally at a dose of 5 g / kg in suspension of the Youngneung extract of Example 1 of the present invention in 0.5% methylcellulose solution. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed. Hematological and hematological examinations were performed, and autopsy was performed to observe abdominal and thoracic organ abnormalities.
  • the present inventors have confirmed that the brain cancer treatment effect of the Yeongneung-hyang extract is excellent through the above Example to prepare a brain cancer treatment containing the Yeongneung-hyang extract as an active ingredient as follows.
  • the preparation of the following therapeutic agent can be used for the application of the health food as well as the therapeutic agent.
  • the present inventors confirmed that Yeongneung-hyang extract is excellent in the brain cancer treatment activity through the above-described embodiment to prepare a functional food containing it as an active ingredient as follows.
  • Chewing gum was prepared using a conventional method using the composition and content of 20% of gum base, 76.36 to 76.76% of sugar, 0.24 to 0.64% of Youngneung extract, 1% of fruit flavor, and 2% of water.
  • composition and content of sugar 34.36 to 34.76%, cocoa butter 34%, cocoa mass 15%, cocoa powder 15%, lecithin 0.5%, vanilla 0.5%, Youngneung extract 0.24 ⁇ 0.64% using the conventional method Chocolate was prepared.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Botany (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une nouvelle utilisation d'extraits de lysimachiae foenum-graeci herba. Plus particulièrement, la présente invention concerne une composition destinée à prévenir et à traiter le cancer du cerveau, ladite composition contenant, en tant que principes actifs, des extraits d'éthanol provenant de lysimachiae foenum-graeci herba. La présente invention porte en outre sur un aliment fonctionnel destiné à la prévention du cancer du cerveau, comprenant des additifs alimentaires cytologiquement acceptables et contenant, en tant que principes actifs, des extraits d'éthanol provenant de lysimachiae foenum-graeci herba. La composition et l'aliment fonctionnel destinés au traitement du cancer du cerveau selon la présente invention peuvent avoir pour effet d'inhiber la croissance des cellules cancéreuses du cerveau et d'induire l'apoptose ; ils peuvent ainsi être utilisés efficacement dans le traitement et la prévention du cancer du cerveau.
PCT/KR2012/000504 2011-01-19 2012-01-19 Composition et aliment naturel fonctionnel comprenant des extraits de lysimachiae foenum-graeci herba utilisés dans le traitement du cancer du cerveau WO2012099422A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0005478 2011-01-19
KR1020110005478A KR101727708B1 (ko) 2011-01-19 2011-01-19 뇌암 치료용 조성물 및 영릉향 추출물의 제조방법

Publications (2)

Publication Number Publication Date
WO2012099422A2 true WO2012099422A2 (fr) 2012-07-26
WO2012099422A3 WO2012099422A3 (fr) 2012-12-06

Family

ID=46516255

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/000504 WO2012099422A2 (fr) 2011-01-19 2012-01-19 Composition et aliment naturel fonctionnel comprenant des extraits de lysimachiae foenum-graeci herba utilisés dans le traitement du cancer du cerveau

Country Status (2)

Country Link
KR (1) KR101727708B1 (fr)
WO (1) WO2012099422A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000010275A (ko) * 1998-07-31 2000-02-15 성재갑 피부 미백용 조성물
CN1876158A (zh) * 2006-04-20 2006-12-13 朱国豪 一种治疗癌症肿瘤的土家族医药验方
US20100151057A1 (en) * 2007-06-08 2010-06-17 Newgex Inc. Medicinal herbal extract having anti-obesity effect
KR20100098317A (ko) * 2009-02-27 2010-09-06 비알엔사이언스 주식회사 골 질환의 예방 및 치료용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100875247B1 (ko) * 2008-09-12 2008-12-19 주식회사 뉴젝스 영릉향 추출물을 유효성분으로 함유하는 대사성 질환의 예방 및 치료용 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000010275A (ko) * 1998-07-31 2000-02-15 성재갑 피부 미백용 조성물
CN1876158A (zh) * 2006-04-20 2006-12-13 朱国豪 一种治疗癌症肿瘤的土家族医药验方
US20100151057A1 (en) * 2007-06-08 2010-06-17 Newgex Inc. Medicinal herbal extract having anti-obesity effect
KR20100098317A (ko) * 2009-02-27 2010-09-06 비알엔사이언스 주식회사 골 질환의 예방 및 치료용 조성물

Also Published As

Publication number Publication date
KR20120084130A (ko) 2012-07-27
WO2012099422A3 (fr) 2012-12-06
KR101727708B1 (ko) 2017-04-17

Similar Documents

Publication Publication Date Title
WO2012108749A2 (fr) Composition et alimentation fonctionnelle pour traiter le cancer du cerveau comprenant un extrait de graines de pharbitis
WO2012134169A2 (fr) Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait de semence de gleditsiae
WO2012108748A2 (fr) Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait d'albizzia julibrissin
WO2012108747A2 (fr) Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait de la racine d'helena
WO2012108745A2 (fr) Composition et alimentation fonctionnelle pour traiter le cancer du cerveau comprenant un extrait de gleditsiae semen
WO2012099420A2 (fr) Composition et aliment fonctionnel comprenant des extraits d'élécampane et destinés au traitement du cancer du cerveau
WO2012108744A2 (fr) Composition et alimentation fonctionnelle pour traiter le cancer du cerveau comprenant un extrait de la fleur inula
WO2012108746A2 (fr) Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait de racine de rubia cordifolia
WO2012108743A2 (fr) Composition et composition cosmétique pour traiter le cancer du cerveau comprenant un extrait des graines de pharbitis blanc
WO2012134252A2 (fr) Composition pour le traitement du cancer du rein et aliment fonctionnel contenant un extrait de semence de cannabis
WO2012099419A2 (fr) Composition et aliment fonctionnel comprenant des extraits de cirsium japonicum et destinés au traitement du cancer du cerveau
WO2012099424A2 (fr) Composition et aliment naturel fonctionnel comprenant des extraits de fenugrec utilisés dans le traitement du cancer du cerveau
WO2012108742A2 (fr) Composition et l'alimentation fonctionnelle pour traiter le cancer du cerveau comprenant un extrait de fleur tussilago farfara
WO2012099422A2 (fr) Composition et aliment naturel fonctionnel comprenant des extraits de lysimachiae foenum-graeci herba utilisés dans le traitement du cancer du cerveau
KR20120084121A (ko) 사상자 추출물을 포함하는 뇌암 치료용 조성물 및 건강 기능성 식품
KR20120092269A (ko) 백화사설초 추출물을 포함하는 뇌암 치료용 조성물 및 건강 기능성 식품
KR101865377B1 (ko) 익지인 추출물을 포함하는 뇌암 치료용 조성물 및 건강 기능성 식품
KR20120092274A (ko) 애엽 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물
KR20120080675A (ko) 마자인 추출물을 포함하는 백혈병 치료용 조성물 및 건강 기능성 식품
WO2014069695A1 (fr) Composition pour traiter le cancer du pancréas et aliment santé fonctionnel contenant un extrait de boswellia
WO2012093917A2 (fr) Composition comprenant de l'extrait de tussalingo farafara l. et aliment santé fonctionnel
KR101865374B1 (ko) 고량강 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물
KR20180027447A (ko) 대계근 추출물을 포함하는 뇌암 치료용 조성물
WO2013147340A1 (fr) Composition et complément alimentaire pour traiter le cancer du poumon, contenant un extrait d'encens
WO2012134251A2 (fr) Composition pour le traitement du cancer du pancréas et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12736269

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12736269

Country of ref document: EP

Kind code of ref document: A2